Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

4.1K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
4.1K
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

3.3K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.3K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

2.2K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
2.2K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.2K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.2K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

626
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
626
Chronic Obstructive Pulmonary Disease-V: Nursing Management01:30

Chronic Obstructive Pulmonary Disease-V: Nursing Management

5.5K
Nursing management of Chronic Obstructive Pulmonary Disease (COPD) is crucial for providing thorough care and support to patients. Nurses play an integral role in this process through detailed assessment, careful planning, targeted interventions, and ongoing evaluation. Here's an overview of the critical steps in nursing management for COPD.
Assessment
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Olive Oil and the Impact of Gastrointestinal Adverse Events During Pirfenidone Treatment in Idiopathic Pulmonary Fibrosis: A Post-hoc Analysis of the MADIET Trial.

Archivos de bronconeumologia·2026
Same author

Disease Mechanisms and Therapeutic Advances in Idiopathic and Progressive Pulmonary Fibrosis: From Approved Drugs to Emerging Strategies.

Journal of clinical medicine·2026
Same author

Lipoid Pneumonia: HRCT and MRI Spectrum, Diagnostic Pitfalls, and Imaging-Based Diagnostic Workflow.

Diagnostics (Basel, Switzerland)·2026
Same author

miR-205-5p promotes endothelial dysfunction and senescence in pulmonary fibrosis.

JCI insight·2026
Same author

Sex-Dependent Integration of Symptoms and Functional Vulnerability in Interstitial Lung Disease: eurILDreg Study.

Respiration; international review of thoracic diseases·2026
Same author

Beyond overlap: a Ro52-driven glandular-pulmonary phenotype at the interface of Sjögren disease and anti-synthetase syndrome in a multicentre cohort.

Frontiers in immunology·2026
Same journal

Clinical remission in elderly patients with sarcoidosis.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2026
Same journal

A case of a rapidly progressing, recurrent orbital mass.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2026
Same journal

Composite Inflammatory Indices for the Differentiation of Tuberculosis, Sarcoidosis, and Reactive Lymphadenopathy in Patients Undergoing EBUS-TBNA.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2026
Same journal

Supervised Home-Based Telerehabilitation for Idiopathic Pulmonary Fibrosis: A Pragmatic Service Evaluation in Routine Care with Detraining Follow-up.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2026
Same journal

Transcriptomic profiling of collagen gene expression in lung fibroblasts from patients with idiopathic pulmonary fibrosis.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2026
Same journal

Unveiling novel susceptibility genes for sarcoidosis by a cross-tissue transcriptome-wide association study.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2026
See all related articles

Related Experiment Video

Updated: Apr 6, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

1.3K

IPF, comorbidities and management implications.

Carlo Vancheri1, Vincent Cottin, Michael Kreuter

  • 1Regional Centre for Rare Pulmonary Diseases, Department of Clinical and Experimental Medicine, University of Catania, Italy. redazione@mattioli1885.com.

Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG
|August 4, 2015
PubMed
Summary
This summary is machine-generated.

Idiopathic pulmonary fibrosis (IPF) frequently co-occurs with cardiovascular disease, lung cancer, and emphysema. These comorbidities worsen prognosis and complicate treatment, highlighting the need for further research into IPF management.

More Related Videos

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
03:38

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

1.1K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

21.1K

Related Experiment Videos

Last Updated: Apr 6, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

1.3K
Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
03:38

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

1.1K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

21.1K

Area of Science:

  • Pulmonary Medicine
  • Cardiology
  • Oncology

Background:

  • Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with numerous comorbidities.
  • Cardiovascular disease (CVD) is the most common comorbidity, increasing mortality risk in IPF patients.
  • Lung cancer and emphysema are also significant comorbidities, complicating diagnosis and treatment.

Purpose of the Study:

  • To review the impact of common comorbidities on IPF prognosis and treatment.
  • To discuss the challenges in managing IPF patients with CVD, lung cancer, and emphysema.

Main Methods:

  • Literature review of studies on IPF comorbidities.
  • Analysis of the clinical implications of CVD, lung cancer, and CPFE in IPF patients.

Main Results:

  • IPF patients with CVD face increased mortality, with unclear causality.
  • Lung cancer affects over 50% of IPF patients within 10 years, worsening prognosis.
  • Combined pulmonary fibrosis and emphysema (CPFE) syndrome presents unique challenges, including high rates of pulmonary hypertension.

Conclusions:

  • Comorbidities significantly impact IPF outcomes, limiting treatment options.
  • Further research is needed to evaluate IPF therapies in patients with comorbidities, particularly CPFE.